Want to see SER full AI Analyst Report?
Top Page
Serina Therapeutics
(SER)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▼(-2.44% Downside)
Action:Reiterated
Date:06/25/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and significant ongoing cash burn). Technicals are neutral-to-slightly positive in the near term, but longer-term trend indicators are still mixed. Valuation provides limited support due to a negative P/E and no dividend yield, while corporate actions add funding flexibility but introduce meaningful dilution risk.
Positive Factors
Proprietary delivery platform
Serina’s polymer-based drug-delivery platform can be paired with existing or novel drugs across disease areas, enabling product diversification, licensing and partnership paths. A platform model supports scalable R&D investments and multiple commercialization routes over the medium term.
Negative Factors
High cash burn
Trailing twelve-month operating and free cash flow are deeply negative (~-$18.2M), indicating material cash burn. Persistent outflows mean the company cannot self-fund development, increasing reliance on external financing and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary delivery platform
Serina’s polymer-based drug-delivery platform can be paired with existing or novel drugs across disease areas, enabling product diversification, licensing and partnership paths. A platform model supports scalable R&D investments and multiple commercialization routes over the medium term.
Read all positive factors
Serina Therapeutics (SER) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.94M
Dividend YieldN/A
Average Volume (3M)24.47K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.97
Shares Outstanding14,997,505
10 Day Avg. Volume14,098
30 Day Avg. Volume24,472
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside363.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.95
Revenue Forecast (FY)N/A
Serina Therapeutics Business Overview & Revenue Model
Company Description
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The compa...
How the Company Makes Money
null...
Serina Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 130.00K | 0.00 | 56.00K | 3.15M | 500.00K | 3.46M |
| Gross Profit | -6.96M | 0.00 | -138.00K | 3.06M | 500.00K | -333.84K |
| EBITDA | -21.17M | -18.91M | -10.49M | 5.92M | -2.60M | -1.23M |
| Net Income | -21.27M | -19.18M | -11.14M | 5.27M | -2.68M | -1.26M |
Balance Sheet | ||||||
| Total Assets | 27.30M | 6.95M | 6.72M | 8.97M | 3.24M | 3.15M |
| Cash, Cash Equivalents and Short-Term Investments | 24.53M | 3.06M | 3.67M | 7.62M | 645.00K | 584.00K |
| Total Debt | 3.17M | 196.00K | 268.00K | 3.44M | 18.12M | 13.20M |
| Total Liabilities | 9.67M | 6.99M | 6.22M | 41.26M | 20.56M | 15.03M |
| Stockholders Equity | 17.63M | -37.00K | 641.00K | 4.11M | -17.21M | -11.83M |
Cash Flow | ||||||
| Free Cash Flow | -18.24M | -17.95M | -17.16M | -2.98M | -2.09M | -2.36M |
| Operating Cash Flow | -18.20M | -17.95M | -17.14M | -2.48M | -2.08M | -2.25M |
| Investing Cash Flow | -84.00K | -59.00K | -22.00K | -504.00K | 980.94K | 823.32K |
| Financing Cash Flow | 38.55M | 17.41M | 13.21M | 10.07M | 1.31M | 1.08M |
Serina Therapeutics Technical Analysis
Positive
2.05
Price Trends
1.87
Positive
1.90
Positive
2.70
Negative
Market Momentum
0.05
Negative
56.45
Neutral
34.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Positive. The current price of 2.05 is above the 20-day moving average (MA) of 1.99, above the 50-day MA of 1.87, and below the 200-day MA of 2.70, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 56.45 is Neutral, neither overbought nor oversold. The STOCH value of 34.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SER.
Serina Therapeutics Risk Analysis
Serina Therapeutics disclosed 69 risk factors in its most recent earnings report. Serina Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Serina Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $222.61M | -1.02 | 178.08% | ― | ― | ― | |
48 Neutral | $31.94M | -1.08 | -402.16% | ― | ― | ― | |
44 Neutral | $22.69M | -0.43 | -70.57% | ― | -100.00% | 21.30% | |
42 Neutral | $22.82M | -0.45 | -217.27% | ― | ― | -74.39% | |
41 Neutral | $22.59M | -0.21 | 411.46% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
SER
Serina Therapeutics
2.18
-3.17
-59.25%
OTLK
Outlook Therapeutics
1.38
-0.68
-33.01%
SKYE
Skye Bioscience
0.65
-3.08
-82.49%
CELU
Celularity
0.78
-2.37
-75.24%
BRNS
Barinthus Biotherapeutics
0.62
-1.35
-68.73%
JUNS
Jupiter Neurosciences, Inc.
0.17
-1.61
-90.68%
Serina Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Serina Therapeutics Shareholders Approve Expanded Equity and Governance
Positive
Jun 24, 2026
On June 17, 2026, Serina Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, at which shareholders approved an amendment to increase the company’s authorized common stock from 40 million to 125 million shares and elected three d...
Business Operations and StrategyExecutive/Board Changes
Serina Therapeutics Updates Executive Leadership and Governance Structure
Positive
Apr 21, 2026
On April 20, 2026, Serina Therapeutics (AL), Inc., a wholly owned subsidiary of Serina Therapeutics, Inc., promoted Srini Tenjarla, Ph.D., from Senior Vice President of CMC and Formulation to Chief Technology Officer and increased his annual base ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.